Bharat Biotech International Ltd on Friday said its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in children and adolescents of 2-18 years age group in phase II/III study. The company conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 years of age group between June 2021 to…
in Lifestyle
Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech
